Pfizer-Acquired Seagen's Adcetris Combo Therapy Extends Overall Survival Versus Placebo In Patients With Most Common Type Of Lymphoma
Portfolio Pulse from Vandana Singh
Pfizer Inc (NYSE:PFE) announced positive results from a Phase 3 study of Adcetris combined with lenalidomide and rituximab for treating diffuse large B-cell lymphoma (DLBCL), showing significant improvement in overall survival compared to a placebo combination. This marks the third Phase 3 study where an Adcetris combination has shown an overall survival benefit in lymphoma treatment. The results are notable for evaluating heavily pre-treated patients. Pfizer acquired Adcetris through its $43 billion acquisition of Seagen Inc. PFE shares saw a slight decrease of 0.09% in premarket trading.
March 12, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's successful Phase 3 study of Adcetris for DLBCL demonstrates a significant advancement in lymphoma treatment, potentially strengthening its oncology portfolio.
The positive results from the Phase 3 study of Adcetris not only underscore Pfizer's commitment to expanding its oncology portfolio but also signal potential future revenue growth from this treatment. Given the significance of these results and the acquisition of Seagen Inc., this news is likely to have a positive short-term impact on Pfizer's stock, despite the slight premarket decrease.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100